Europe’s Mosquito-Borne Disease Challenge Is Changing — Are We Ready?

For years, mosquito-borne viruses were easy to file under “travel medicine” in much of Europe: something that happened elsewhere, or briefly after a holiday. That mental map is now outdated. European surveillance is tracking persistent West Nile virus seasons, unusually large local chikungunya activity, recurrent dengue clusters, expanding Aedes mosquitoes, and — just as important — uneven national capacity to monitor and control them. The useful question is not whether Europe faces “tropicalisation” as a slogan. It is whether detection, vector control, clinical awareness, laboratory confirmation, blood safety, local response, and cross-border coordination are being built at the same pace as ecological suitability.

What changed: local transmission is no longer rare news

Local dengue in Europe rose from 71 cases in 2022 to 130 in 2023 and 304 in 2024 — then the highest annual total WHO/Europe had summarised since surveillance began. That sequence mattered. It did not, however, establish a permanent year-on-year rise. By 12 November 2025, ECDC seasonal surveillance had recorded 35 locally acquired dengue cases in Europe (France 29, Italy 4, Portugal 2, with the Portuguese cases in Madeira). Early in the 2026 season, as of 2 September, France and Italy had reported eight local dengue cases between them. The honest reading is volatility under favourable conditions for Aedes transmission — not a straight line upward.

Locally acquired dengue cases in Europe: 71 in 2022, 130 in 2023, 304 in 2024, and 35 in 2025.

71

2022

130

2023

304

2024

35

2025

Sources: ECDC (2022–2024 totals summarised 1 July 2025); ECDC CDTR week 46, 2025 (2025 as of 12 November).

Chikungunya tells a different 2025 story — and it should carry more weight in any current European assessment. Santé publique France identified 809 locally acquired cases in mainland France during enhanced surveillance from May to November 2025, with symptom onsets from late May to mid-November and transmission episodes reaching regions affected for the first time. ECDC, as of mid-November 2025, recorded 384 locally acquired cases in Italy alongside hundreds in France. In 2026, local transmission continued at a smaller scale: as of 2 September, France alone had reported 46 locally acquired chikungunya cases to ECDC. The point is not that every summer will match 2025. It is that Europe has now demonstrated the capacity for large, multi-region Aedes-borne outbreaks when imported virus meets established vectors and a long warm season.

West Nile virus remains the larger seasonal human burden in absolute counts. In 2024, ECDC summarised 1,436 infections across 212 regions in 19 countries. In 2025, as of early November, 14 countries had already reported 1,096 locally acquired cases. By 3 September 2026 — still within the high-risk weeks of the season — ECDC’s weekly overview counted 1,086 locally acquired human cases across 144 areas in 15 countries, with Italy and Greece carrying the heaviest loads and several areas newly affected that week. ECDC also noted that six European regions reported locally acquired West Nile virus infections for the first time in 2026. That is not a curiosity season. It is a recurring late-summer public-health workload involving human cases, animal surveillance, blood-safety decisions, and clinicians who may still treat neuroinvasive disease as unlikely.

Vectors are the slow crisis underneath the case counts

Case totals rise and fall with weather, surveillance intensity, and chance introductions. Vector establishment is stickier. ECDC identifies Aedes albopictus as a key concern for dengue, chikungunya and Zika; Culex mosquitoes for West Nile virus; and notes that Aedes aegypti — once eliminated from Europe — has re-emerged in places such as Cyprus. On World Mosquito Day 2026, ECDC again stated that Aedes albopictus is established in 16 European countries — double the number from 12 years earlier. WHO/Europe, using the wider WHO European Region, had reported establishment in 30 countries as of June 2025. The figures are not interchangeable — different geographies — but they point the same way: the mosquito map is expanding faster than public attention usually does.

That matters because local outbreaks of Aedes-borne disease in Europe still usually begin with importation. Without mosquitoes capable of transmitting the virus nearby, an imported dengue or chikungunya case is a clinical episode. With them, it can become a cluster. ECDC’s guidance is explicit: intensive international travel facilitates virus importation, while secondary local transmission is driven mainly by invasive Aedes species under favourable summer conditions that climate change is expected to lengthen.

A brief comparison, not a distraction

A short US note still helps keep European numbers in proportion. CDC’s MMWR analysis found a record 3,798 dengue cases in the 50 states and District of Columbia in 2024 — mostly travel-associated, with 105 locally acquired. Local transmission did not become a large continental outbreak, but CDC reads the pattern as rising introduction risk where Aedes mosquitoes are present. The comparison is useful only as a parallel: temperate and subtropical settings with travel links and competent vectors now share a preparedness problem. Europe’s current evidence — especially West Nile virus in 2026 and chikungunya in 2025 — is already strong enough without treating US dengue as the main story.

“Are we ready?” is a systems question

ECDC’s July 2025 Aedes-borne disease guidance already refused a single continental answer: preparedness varies, and actions should follow graded risk levels based on vector presence, environmental conditions, recent transmission, receptivity and vulnerability — including whether health systems can detect infections promptly and interrupt onward spread. The August 2026 questionnaire report makes that unevenness concrete. Of 38 countries and jurisdictions contacted, 26 responded. Between 2020 and 2025, Culex surveillance ran in 17 countries and control in 12; Aedes invasive mosquito surveillance in 20 and control in 17. Activities were often constrained by short-term funding and limited long-term planning. Reactive control remained largely ad hoc and focused on adult mosquitoes; durable elimination strategies were frequently missing. Organisation sat variously at national, regional or local level — which helps explain why cross-border coordination is hard even when ecology does not respect borders.

So what would “ready” look like in practice? Not perfect elimination of mosquitoes. A more honest checklist is whether clinicians recognise atypical summer febrile syndromes; whether laboratories can confirm dengue, chikungunya, Zika and West Nile virus without long delay; whether entomological surveillance and breeding-site management exist before the first cluster, not only after headlines; whether blood services have clear triggers for deferral or testing; whether local authorities can mount timely, proportionate response; and whether returning travellers are advised that personal protection still matters for weeks after arrival where competent vectors are present. ECDC’s public advice — repellents, clothing, screens, removing standing water — remains necessary. It is not sufficient if public systems wait for case counts to announce that the ecology has already changed.

Closing

Europe’s mosquito-borne disease challenge is changing in the sense that matters for public health: West Nile virus seasons that repeatedly exceed a thousand cases and keep reaching new areas; a 2025 chikungunya season that showed how large local Aedes-borne outbreaks can become; dengue that peaks and retreats rather than climbing forever; and vectors established across a widening European map. It is not becoming a carbon copy of tropical endemicity, and treating every summer as an impending continental epidemic would overstate the evidence.

The better test of readiness is quieter — and more operational. Can countries move from surprise to routine: planned entomological and disease surveillance, early detection, laboratory capacity, blood-safety triggers, local response capacity, and boringly consistent vector management? ECDC’s 2026 capacity findings suggest Europe is only partly there. The ecology is already rehearsing the next seasons. Public health still has time to rehearse with it — if it treats preparedness as infrastructure, not as a reaction to the latest outbreak map.

Sources & further reading

1. ECDC — Surveillance of West Nile virus infections in humans in Europe, weekly report (Week 36, 2026; data to 3 September)
2. ECDC — Communicable Disease Threats Report, 29 August–4 September 2026 (Week 36): dengue and chikungunya seasonal updates
3. ECDC — World Mosquito Day 2026: Europe must upgrade control tools as disease risks rise (20 August 2026)
4. ECDC — Surveillance and control of Culex mosquitoes and Aedes invasive mosquitoes in Europe: questionnaire findings (20 August 2026)
5. ECDC — Communicable Disease Threats Report, week 46, 2025 (local dengue and chikungunya end-of-season surveillance figures)
6. Santé publique France — Chikungunya, dengue and Zika in metropolitan France: 2025 report (809 locally acquired chikungunya cases)
7. ECDC — Public health guidance for assessing and mitigating the risk of locally-acquired Aedes-borne viral diseases in the EU/EEA (1 July 2025)
8. WHO/Europe — Dengue and West Nile virus: updates from the WHO European Region (2025)
9. CDC MMWR — Increase in travel-associated and locally acquired dengue cases — United States, 2024
10. ECDC — New weekly reports and guidance to tackle mosquito-borne diseases across Europe (1 July 2025; 2022–2024 dengue and 2024 West Nile summaries)